软肝冲剂对慢性乙肝患者血浆中的TGF-β1,MMP-1和TIMP-1浓度的影响  

Effect of Ruanganchengji treatment on plasma levels of TGF-β1, TIMP-1and MMP-1 in patients with chronic hepatitis B

作　　者：莫其农 黄涛 方晓艺 周小梅 何进才 贺劲松 周小舟 童光东 熊益群 周大桥 Mo qinong, Huang tao, Fang xiaoyi, et al. （Laboratory medicine, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, 518033, China）

机构地区：广东省广州中医药大学附属深圳市中医院,518033

出　　处：《中外健康文摘：医药月刊》2007年第7期104-107,共4页

基　　金：深圳市科技局立项项目（项目编号：JH200507130988A）

摘　　要：目的 研究软肝冲剂对慢性乙肝患者血浆中的TGF-β1、TIMP-1和MMP-1的影响。方法选择HBsAg,HBeAb和HBV-DNA阳性的患者分三组,分别用软肝冲剂,拉米夫啶和软肝冲剂和拉米夫啶联合治疗,用ELISA方法检测患者在治疗前和治疗过程中2,4,和6月的血浆中的、TIMP-1和MMP-1的浓度以及主要生化指标ALT、AST。结果软肝冲剂同拉米夫啶一样能有效地降低血浆中的TGF-β1、TIMP-1的浓度,提高血浆中的MMP-1的浓度,软肝冲剂与拉米夫啶联合治疗作用更明显。并且TGF-β1、TIMP-1与ALT和AST有一定的相关性。结论软肝冲剂能降低慢性乙肝患者血浆中、TIMP-1的浓度,提高血浆中的MMP-1浓度,对慢性乙肝患者的肝纤维化和肝硬化具有明显的治疗作用。Objective： The aim is to study the effect of Ruanganchengji treatment on plasma levels of TGF-β1 ,TIMP-land MMP-1 in chronic hepatitis B patients. Methods： Chronic hepatitis B patients with HBsAg , HBeAb and HBV-DNA positive were selected to be treated using either Ruanganchengji or lamivudine and both. And plasma levels of TGF-β1, TIMP-land MMP-1 and major biochemical index ALTand AST were measured using ELISAduring the treatment. Results： Ruanganchengji could decrease the plasma levels of TGF- β1, TIMP-1, and increase the level of MMP-1 after treatment, similar to that of lamivudine-treated group. Furthermore, the levels of TGF- β1, TIMP-1 were proportional to that of ALT and AST. Conclusions： Ruanganchengji could treat liver fibrosis and Live cirrhosis through the decrease of and TIMP-1 levels and increase of that of MMP-1 in patients with chronic hepatitis B.

关 键 词：慢性乙肝 拉米夫啶 软肝冲剂 TGF-Β1 TIMP-1 MMP-1 

分 类 号：R512.62[医药卫生—临床医学;医药卫生—内科学]